Quantcast

Wednesday, February 18, 2009

Drug for Premature Ejaculation

A new drug has been designed that can treat premature ejaculation.  A major pharmaceutical company, Janssen-Ortho Inc., has filed an application with Health Canada to market the drug, dapoxetine, known by the brand name Priligy, in the country. Dapoxetine (brand name Priligy) is a short-acting SSRI drug for the treatment of premature ejaculation in men. Dapoxetine is the only drug with regulatory approved for such treatment. Currently, it is approved for use in Finland and Sweden and is being considered for approval in other European countries and in the United States where it is currently in Phase III of the FDA approval process. However, experts have claimed that the drug is not 100 percent successful.  "This is a really common problem," Globeandmail.com quoted Gerald Brock, a professor at the University of Western Ontario, as saying.  Brock, who has been involved with company-sponsored trials of the drug, has said that the condition can cause great emotional distress for men and their partners, and is believed to affect up to one-third of males. He revealed that, basically, these men lack sexual control and reach orgasm in less than two minutes. For a long time, scientists have suspected that serotonin plays a role in the disorder. And, sometimes patients are treated with a class of antidepressants known as SSRIs (selective serotonin reuptake inhibitors), which affect serotonin levels.  "The problem with SSRIs is that they are very slow to start working and they stay in your body for a long time," explained Brock.  And in order to treat premature ejaculation, an SSRI must be taken every day. Thus, scientists designed Priligy, which need to be taken about one to three hours before sexual intercourse.

Free Books, powerpoint presentations, teaching tools and resources and drug information